Common Cause Links Small Cell Prostate and Lung Carcinomas

​ Researchers have discovered that the same set of oncogenes reprograms healthy human prostate and lung epithelial cells into small cell prostate cancer (SCPC) and small cell lung cancer (SCLC). This breakthrough, the first to clearly describe the steps in these cancers' shared evolution, could lead to the development of drugs targeting multiple types of small cell neuroendocrine carcinoma (SCNC) through a single mechanism. An unfortunate consequence has resulted from powerful targeted therapies...
Continue reading

Metastatic Merkel Cell Carcinoma: Treatment Challenges and Best Practices With Paul Nghiem, MD, PhD

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 1,500 cases are diagnosed in the United States annually. The rapid rise of MCC incidence during the past few decades has been attributed in part to people living longer with increased sun exposure and weakened immune systems, a feature that suggests an infectious origin and warrants further research. Treatment standards are ...
Continue reading

Iobenguane I 131 Approved for Treatment of Adrenal Gland Tumors

The FDA has granted approval to iobenguane I 131 (Azedra, Progenics Pharmaceuticals, Inc.) for the treatment of iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL)—rare neuroendocrine tumors with a poor prognosis and limited treatment options—in adult and pediatric patients who require systemic anticancer therapy. Approval was based on an open-label, single-arm, multicenter clinical trial which evaluated 68 patients (aged ≥12 years) wit...
Continue reading

Lutetium Lu 177 Dotatate Approved for GEP-NETS

The FDA approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc.) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Approval was based on data from NETTER-1, a randomized, multicenter, open-label, active-controlled trial in 229 patients with progressive, well-differentiated, locally advanced/inoperable or metastatic som...
Continue reading
© Copyright 2018 i3 Health. All rights reserved.